Annuncio pubblicitario
Italia markets close in 4 hours 25 minutes
  • FTSE MIB

    34.780,78
    +21,09 (+0,06%)
     
  • Dow Jones

    39.760,08
    +477,75 (+1,22%)
     
  • Nasdaq

    16.399,52
    +83,82 (+0,51%)
     
  • Nikkei 225

    40.168,07
    -594,66 (-1,46%)
     
  • Petrolio

    82,42
    +1,07 (+1,32%)
     
  • Bitcoin EUR

    65.594,85
    +411,77 (+0,63%)
     
  • CMC Crypto 200

    885,54
    0,00 (0,00%)
     
  • Oro

    2.230,80
    +18,10 (+0,82%)
     
  • EUR/USD

    1,0789
    -0,0041 (-0,38%)
     
  • S&P 500

    5.248,49
    +44,91 (+0,86%)
     
  • HANG SENG

    16.541,42
    +148,58 (+0,91%)
     
  • Euro Stoxx 50

    5.088,80
    +7,06 (+0,14%)
     
  • EUR/GBP

    0,8549
    -0,0018 (-0,21%)
     
  • EUR/CHF

    0,9766
    -0,0019 (-0,19%)
     
  • EUR/CAD

    1,4661
    -0,0026 (-0,17%)
     

Saniona CEO Thomas Feldthus and board member Carl Johan Sundberg purchase Saniona shares in the open market

Saniona AB
Saniona AB

PRESS RELEASE

July 6, 2022

Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the CEO and a member of the Board of Directors have purchased 240,221 shares of the company in the open market for a total value of approximately SEK 0.9 million.

Saniona CEO Thomas Feldthus bought 200,221 shares in the company for a total investment of SEK 785,683. Saniona board member Carl Johan Sundberg bought 40,000 shares in the company for a total investment of SEK 142,128. All transactions have been made in the open market during the period from July 1 to July 5, 2022.

For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

ANNUNCIO PUBBLICITARIO

This information was submitted for publication, through the agency of the contact person set out above, at 08.00 CEST on July 6, 2022.

About Saniona
Saniona is a clinical-stage biopharmaceutical company with a mission to leverage its ion channel targeting expertise to discover, develop and deliver innovative rare disease treatments. The company’s most advanced product candidate, Tesomet™, has been progressed into mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE™, a database of more than 130,000 compounds, of which more than 20,000 are Saniona’s proprietary ion channel modulators. Through its ion channel expertise, Saniona is advancing two wholly owned ion channel modulators, SAN711, SAN903. SAN711 has successfully completed a Phase 1 clinical trial and is positioned for the treatment of neuropathic pain conditions; SAN903 is in preclinical development for rare inflammatory, fibrotic, and hematological disorders. Saniona is based in the Copenhagen area, Denmark, and is listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com.

Attachment